In 2021, Automated is Expected to Dominate the Market with a 63.22% Market Share

An immunoassay is a biochemical test that uses an antibody or antigen to determine the presence or concentration of a macromolecule or a small molecule in a solution. A gadget known as a "Gamma Counter" is used to perform the biochemical test. A gamma counter is a device that measures the amount of gamma radiation produced by a radionuclide. Gamma counters, unlike survey meters, are designed to measure small quantities of radioactive material, usually with automated measurement and sample movement.   ​

Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/global-immunoassay-gamma-counters-market

Global immunoassay-gamma counters market is expected to reach USD 93.76 million by 2028 from USD 61.87 million in 2020, growing with a CAGR of 5.5% in the forecast period of 2021 to 2028. The market for immunoassay-gamma counters has grown in both developed and developing countries, owing to an increase in worldwide healthcare spending. Due to increased government backing and increased approval of innovative technological items, the immunoassay-gamma counters industry is growing. With an increase in strategic activities by industry participants, the market will grow during the anticipated period.   

Increase in prevalence of chronic diseases will drive the market's growth rate

Chronic Disease Management (CDM) is ongoing care and support to assist individuals impacted by a chronic health condition with the medical care, knowledge, skills, and resources they need to better manage daily. Chronic diseases include Asthma, COPD and Lung Health, Brain Injury, Chronic Pain, Dementia, Diabetes, Heart Health, Renal (Kidney), Stroke, and Mental health, among others.

Chronic diseases affecting a huge number of people across the world and the increased burden of chronic disease is expected to increase research programs and use of gamma radiation. This is driving the growth of the market. Increased expenditure by public and private players on infrastructure development will also promote the market growth rate. Continuous research and development pertaining to the deployment of advanced technologies will yet again widen the scope of growth.  

Report Scope and Market Segmentation

Segment Analysis:

Global immunoassay-gamma counters market is categorized into seven notable segments which are based on product type, well, application, disease condition, purchase mode, end user, and distribution channel.

• On the basis of product type, the global immunoassay-gamma counters market is segmented into manual/ semi-automated and automated. In 2021, automated is expected to dominate the market with a 63.22% market share due to its automatic optimization and convenience in load and unload.
• On the basis of well, the global immunoassay-gamma counters market is segmented into single-well and multi-well. In 2021, multi-well segment is expected to dominate the market with a 63.52% market share as these instrument offers sophisticated single detector gamma counter.
• On the basis of application, the global immunoassay-gamma counters market is segmented into radioimmunoassay and nuclear medicine assays and others. In 2021, the radioimmunoassay tools segment is expected to dominate the market with a 51.95% market share due to its application in detecting gamma emissions in the scintillation counter and advantages over conventional mycotoxin assays.
• On the basis of disease condition, the global immunoassay-gamma counters market is segmented into cancer biomarker, neonatal screening, infectious diseases, therapeutic drug monitoring, allergy, endocrine hormones, cardiac markers, autoimmune disease and others. In 2021, cancer biomarker segment is expected to dominate the market with a 26.50% market share due to effective predicting the clinical benefit of treatment with ICIs.
• On the basis of purchase mode, the global immunoassay-gamma counters market is segmented into rental purchase and outright purchase. In 2021, outright purchase segment is expected to dominate the market with a 75.81% market share due to capital allowances can be claimed against products.
• On the basis of end user, the global immunoassay-gamma counters market is segmented into hospitals, laboratory, blood banks, research & academic institutes, pharmaceutical & biotechnology companies and others. In 2021, the laboratory segment is expected to dominate the market with a 28.58% market share due to the rise in the number of gamma counters in hospitals for diagnosis and treatment.

Laboratory segment will dominate the end user segment of the immunoassay-gamma counters market

The laboratory segment will emerge as the dominating segment under end user in 2021 with approximately 29% market share. This is because of the growing number of laboratories in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.

• On the basis of distribution channel, the global immunoassay-gamma counters market is segmented into direct tenders and third party distributors. In 2021, the direct tenders segment is expected to dominate the market with an 84.76% market share due to low cost device procurement and large dependence of hospitals among other end users on direct tenders.

The direct tender segment will dominate the distribution channel segment of the immunoassay-gamma counters market

The direct tender segment will emerge as the dominating segment under distribution channel segment in 2021. This is because of the growing number of direct tenders all over the globe. Further, growth and expansion of distribution channels and services on a global scale will further bolster the growth of this segment.

Major Players              

Data Bridge Market Research recognizes the following companies as the market players in immunoassay-gamma counters market: Hidex Oy (Finland), Perkin Elmer Inc (U.S.), Berthold Technologies GmbH & Co. KG (Germany), ENERSYS Co. Ltd (U.S.), Shinjin Medics Inc (South Korea) and LabLogic Systems Ltd (U.K.).

Market Development

• In December 2020, LabLogic partnered with Swisstrace preclinical imaging facilities - the MR-compatible Twilite Three system from Swisstrace. This high-sensitivity blood sampler measures the time-course of radioactivity in whole blood for obtaining the arterial input function necessary in dynamic PET imaging.
• PerkinElmer Inc. declared in July 2021 that it will continue to expand its footprint in India by relying on innovative products. The new items will be released in a variety of fields, including research, pharmaceuticals, and food testing. This has aided the company's international expansion.
• Hidex Oy stated in March 2021 that its Gamma Counter product has been improved with a sample QR scanner, which allows for sample identification and complies with FDA 21 Part 11 requirements. This is predicted to enhance demand for the product over the forecasted time and the instrument's efficacy.
• In November 2020, Berthold Technologies GmbH & C0.KG announced that the partial lockdown was ordered to reduce infection rate. However, the company assured to the customers about the reliable delivery as they keep up the production during this time, following the proper guidelines by the government. This helps the company to maintain the demand and generate revenue during the pandemic.

Regional Analysis

Geographically, the countries covered in the immunoassay-gamma counters market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in immunoassay-gamma counters market during the forecast period 2021 - 2028

Because of the substantial investment in the region for adopting new healthcare facilities, North America is likely to lead the global market. In addition, the region's market is fueled by the presence of major competitors.

Asia-Pacific is estimated to be the fastest-growing region in immunoassay-gamma counters market the forecast period 2021 - 2028

Asia-Pacific is expected to increase significantly as well and will register the highest growth rate owing to an increase in the region's pet population and increased investments in the healthcare sector. Furthermore, as part of their economic growth aspirations, growing economies in APAC, such as India, are heavily investing in the infrastructure development. Furthermore, increasing investment by multiple organizations in product research and development, particularly in manufacturing in developing countries, is fueling market expansion in the region.

COVID-19 Impact Analysis

The COVID-19 immunoassay product is crucial in controlling the virus's transmission. In the absence of a vaccine or medication, the only effective strategy to limit and manage the spread of illnesses and potential causalities is to diagnose them. Rapid testing have proven to be an effective, quick, and easy molecular test for COVID-19 surveillance on a broad scale. The challenges of SARS-CoV2 detection have been resolved by to extensive research, appraisals, and approvals of many immunoassay consumables and analyzers. Due to the widespread diagnosis of COVID-19, the immunoassay market in various countries has seen tremendous expansion throughout the epidemic. Moreover, as the number of COVID-19 cases rises in the third wave, the market is projected to rise even more.

For more detailed information about the immunoassay-gamma counters on market report, click here – https://www.databridgemarketresearch.com/fr/reports/global-immunoassay-gamma-counters-market